IDEXX Laboratories Company Insiders
| IDXX Stock | USD 411.80 5.31 1.27% |
IDEXX Laboratories' insiders are aggressively selling. The analysis of insiders' sentiment of trading IDEXX Laboratories stock suggests that vertually all insiders are panicking at this time. IDEXX Laboratories employs about 11 K people. The company is managed by 15 executives with a total tenure of roughly 23 years, averaging almost 1.0 years of service per executive, having 733.33 employees per reported executive.
| Michael Lane President Corporate Vice President General Manager |
| Sharon Underberg President Corporate Vice President General Counsel, and Corporate Secretary |
IDEXX Laboratories' Insider Buying Vs Selling
0
Selling | Buying |
Latest Trades
| 2024-11-27 | Sophie V Vandebroek | Disposed 344 @ 420.44 | View | ||
| 2024-05-17 | Bruce L Claflin | Disposed 200 @ 540.8 | View | ||
| 2024-02-08 | George Fennell | Disposed 8198 @ 573.87 | View | ||
| 2024-02-07 | Jonathan Jay Mazelsky | Disposed 12000 @ 572.61 | View |
Monitoring IDEXX Laboratories' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
IDEXX |
IDEXX Laboratories' Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with IDEXX Laboratories' future performance. Based on our forecasts, it is anticipated that IDEXX will maintain a workforce of slightly above 11000 employees by January 2025.IDEXX Laboratories' latest congressional trading
Congressional trading in companies like IDEXX Laboratories, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in IDEXX Laboratories by those in governmental positions are based on the same information available to the general public.
| 2024-02-14 | Senator Tommy Tuberville | Acquired Under $15K | Verify | ||
| 2024-02-13 | Senator Tommy Tuberville | Acquired Under $15K | Verify |
IDEXX Laboratories Management Team Effectiveness
The company has return on total asset (ROA) of 0.2279 % which means that it generated a profit of $0.2279 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.5942 %, meaning that it created $0.5942 on every $100 dollars invested by stockholders. IDEXX Laboratories' management efficiency ratios could be used to measure how well IDEXX Laboratories manages its routine affairs as well as how well it operates its assets and liabilities.IDEXX Laboratories Workforce Comparison
IDEXX Laboratories is rated below average in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 408,459. IDEXX Laboratories holds roughly 11,000 in number of employees claiming about 2.69% of equities under Health Care industry.
The company has Profit Margin (PM) of 0.23 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.37 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.37. IDEXX Laboratories Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific IDEXX Laboratories insiders, such as employees or executives, is commonly permitted as long as it does not rely on IDEXX Laboratories' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, IDEXX Laboratories insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2024-09-01 | 0.5833 | 7 | 12 | 533,437 | 534,277 |
| 2024-06-01 | 3.4444 | 31 | 9 | 11,078 | 2,032 |
| 2024-03-01 | 0.6642 | 89 | 134 | 142,692 | 233,465 |
| 2023-12-01 | 0.4375 | 7 | 16 | 26,807 | 54,826 |
| 2023-09-01 | 0.5517 | 16 | 29 | 195,491 | 250,420 |
| 2023-06-01 | 0.8095 | 34 | 42 | 24,953 | 62,208 |
| 2023-03-01 | 1.1833 | 71 | 60 | 112,250 | 56,054 |
| 2022-12-01 | 0.2857 | 8 | 28 | 64,941 | 114,086 |
| 2022-09-01 | 0.7143 | 5 | 7 | 450,612 | 455,852 |
| 2022-06-01 | 3.375 | 27 | 8 | 16,783 | 2,610 |
| 2022-03-01 | 1.3333 | 76 | 57 | 109,530 | 29,526 |
| 2021-12-01 | 0.3214 | 9 | 28 | 49,092 | 99,146 |
| 2021-09-01 | 0.3582 | 24 | 67 | 36,716 | 78,413 |
| 2021-06-01 | 0.7436 | 29 | 39 | 48,528 | 109,096 |
| 2021-03-01 | 1.012 | 84 | 83 | 172,760 | 139,542 |
| 2020-12-01 | 0.1008 | 12 | 119 | 61,167 | 260,816 |
| 2020-09-01 | 0.3793 | 22 | 58 | 207,426 | 443,703 |
| 2020-06-01 | 0.9189 | 34 | 37 | 128,990 | 292,419 |
| 2020-03-01 | 0.4812 | 64 | 133 | 191,946 | 320,807 |
| 2019-12-01 | 0.5455 | 12 | 22 | 107,422 | 248,815 |
| 2019-09-01 | 0.75 | 27 | 36 | 112,012 | 159,916 |
| 2019-06-01 | 1.1053 | 21 | 19 | 57,765 | 95,599 |
| 2019-03-01 | 0.825 | 66 | 80 | 248,124 | 182,324 |
| 2018-12-01 | 1.0 | 6 | 6 | 8,790 | 43,728 |
| 2018-09-01 | 0.7143 | 25 | 35 | 173,448 | 244,035 |
| 2018-06-01 | 0.6452 | 20 | 31 | 18,847 | 139,394 |
| 2018-03-01 | 0.7778 | 49 | 63 | 283,378 | 267,779 |
| 2017-12-01 | 0.2121 | 7 | 33 | 49,725 | 231,932 |
| 2017-09-01 | 0.6897 | 20 | 29 | 128,414 | 236,196 |
| 2017-06-01 | 1.3333 | 24 | 18 | 135,117 | 213,874 |
| 2017-03-01 | 1.0238 | 43 | 42 | 315,068 | 228,188 |
| 2016-12-01 | 0.4 | 12 | 30 | 86,515 | 259,765 |
| 2016-09-01 | 0.5789 | 11 | 19 | 180,213 | 325,435 |
| 2016-06-01 | 4.2 | 21 | 5 | 70,724 | 24,851 |
| 2016-03-01 | 1.25 | 50 | 40 | 473,799 | 72,298 |
| 2015-12-01 | 0.7273 | 8 | 11 | 39,442 | 49,642 |
| 2015-09-01 | 0.7647 | 13 | 17 | 58,579 | 88,023 |
| 2015-06-01 | 2.4444 | 22 | 9 | 57,016 | 31,676 |
| 2015-03-01 | 0.8852 | 54 | 61 | 286,385 | 245,302 |
| 2014-12-01 | 0.5652 | 13 | 23 | 90,433 | 163,636 |
| 2014-09-01 | 1.4 | 14 | 10 | 48,740 | 43,162 |
| 2014-06-01 | 2.4444 | 22 | 9 | 34,909 | 14,430 |
| 2014-03-01 | 1.2162 | 45 | 37 | 255,611 | 202,219 |
| 2013-12-01 | 0.8421 | 32 | 38 | 362,910 | 530,970 |
| 2013-09-01 | 0.8571 | 6 | 7 | 25,442 | 40,134 |
| 2013-06-01 | 1.5333 | 23 | 15 | 72,806 | 40,328 |
| 2013-03-01 | 0.9714 | 102 | 105 | 429,536 | 572,563 |
| 2012-12-01 | 0.42 | 21 | 50 | 177,995 | 394,152 |
| 2012-09-01 | 0.6 | 27 | 45 | 141,810 | 239,572 |
| 2012-06-01 | 1.1818 | 26 | 22 | 82,212 | 111,342 |
| 2012-03-01 | 1.4615 | 76 | 52 | 238,745 | 99,586 |
| 2011-12-01 | 0.4091 | 9 | 22 | 92,899 | 154,958 |
| 2011-09-01 | 0.6316 | 12 | 19 | 115,509 | 202,241 |
| 2011-06-01 | 0.9394 | 31 | 33 | 225,109 | 289,654 |
| 2011-03-01 | 1.3118 | 122 | 93 | 667,530 | 472,107 |
| 2010-12-01 | 0.75 | 9 | 12 | 185,302 | 283,049 |
| 2010-09-01 | 0.875 | 14 | 16 | 223,305 | 366,914 |
| 2010-06-01 | 0.7826 | 18 | 23 | 220,244 | 362,406 |
| 2010-03-01 | 1.4918 | 91 | 61 | 454,974 | 274,756 |
| 2009-12-01 | 0.6667 | 8 | 12 | 24,793 | 47,916 |
| 2009-09-01 | 0.7857 | 22 | 28 | 116,420 | 201,139 |
| 2009-06-01 | 1.0 | 10 | 10 | 19,718 | 47,406 |
| 2009-03-01 | 2.3125 | 74 | 32 | 339,129 | 14,118 |
| 2008-12-01 | 2.75 | 11 | 4 | 68,554 | 17,424 |
| 2008-09-01 | 0.8077 | 21 | 26 | 137,388 | 229,987 |
| 2008-03-01 | 0.8977 | 79 | 88 | 321,518 | 98,794 |
| 2007-12-01 | 0.6667 | 8 | 12 | 66,199 | 128,992 |
| 2007-09-01 | 0.7391 | 17 | 23 | 47,159 | 84,078 |
| 2007-06-01 | 1.0909 | 12 | 11 | 28,870 | 36,421 |
| 2007-03-01 | 1.617 | 76 | 47 | 340,413 | 212,926 |
| 2006-12-01 | 2.3333 | 7 | 3 | 6,990 | 6,450 |
| 2006-09-01 | 0.3 | 9 | 30 | 21,081 | 105,678 |
| 2006-06-01 | 3.5 | 7 | 2 | 8,955 | 8,400 |
| 2006-03-01 | 2.52 | 63 | 25 | 167,223 | 91,151 |
| 2005-12-01 | 1.0667 | 16 | 15 | 42,075 | 60,962 |
| 2005-09-01 | 0.625 | 15 | 24 | 41,270 | 86,587 |
| 2005-06-01 | 1.6667 | 25 | 15 | 79,016 | 86,420 |
| 2005-03-01 | 5.1667 | 31 | 6 | 156,127 | 18,206 |
| 2004-12-01 | 0.9286 | 13 | 14 | 10,626 | 22,341 |
| 2004-09-01 | 3.6667 | 11 | 3 | 20,402 | 6,415 |
| 2004-06-01 | 1.8 | 9 | 5 | 26,300 | 16,000 |
| 2004-03-01 | 1.28 | 32 | 25 | 167,602 | 79,262 |
| 2003-12-01 | 0.9286 | 26 | 28 | 55,491 | 80,433 |
| 2003-09-01 | 14.0 | 14 | 1 | 118,272 | 3,500 |
| 2003-06-01 | 1.0 | 5 | 5 | 20,000 | 74,300 |
IDEXX Laboratories Notable Stakeholders
An IDEXX Laboratories stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as IDEXX Laboratories often face trade-offs trying to please all of them. IDEXX Laboratories' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting IDEXX Laboratories' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Jonathan Mazelsky | CEO President | Profile | |
| Michael Lane | Corporate Vice President General Manager | Profile | |
| Sharon Underberg | Corporate Vice President General Counsel, and Corporate Secretary | Profile | |
| Brian McKeon | CFO, Principal Accounting Officer, Executive VP and Treasurer | Profile | |
| Nimrata PE | Sector Strategy | Profile | |
| Martin Smith | Executive CTO | Profile | |
| Sharon JD | General VP | Profile | |
| Jeffery Chadbourne | Director Reporting | Profile | |
| George Fennell | Senior Officer | Profile | |
| Ken Grady | Senior Officer | Profile | |
| Kerry Bennett | Senior Labs | Profile | |
| Michael Johnson | Executive Officer | Profile | |
| James Polewaczyk | Executive Officer | Profile | |
| John Hart | Senior Operations | Profile | |
| Michael Erickson | Executive Telemedicine | Profile |
About IDEXX Laboratories Management Performance
The success or failure of an entity such as IDEXX Laboratories often depends on how effective the management is. IDEXX Laboratories management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of IDEXX management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the IDEXX management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
IDEXX Laboratories, Inc. develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine. Idexx Laboratories operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. It employs 10000 people.
Please note, the imprecision that can be found in IDEXX Laboratories' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of IDEXX Laboratories. Check IDEXX Laboratories' Beneish M Score to see the likelihood of IDEXX Laboratories' management manipulating its earnings.
IDEXX Laboratories Workforce Analysis
Traditionally, organizations such as IDEXX Laboratories use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare IDEXX Laboratories within its industry.IDEXX Laboratories Manpower Efficiency
Return on IDEXX Laboratories Manpower
| Revenue Per Employee | 332.8K | |
| Revenue Per Executive | 244.1M | |
| Net Income Per Employee | 76.8K | |
| Net Income Per Executive | 56.3M | |
| Working Capital Per Employee | 49.4K | |
| Working Capital Per Executive | 36.2M |
Additional Tools for IDEXX Stock Analysis
When running IDEXX Laboratories' price analysis, check to measure IDEXX Laboratories' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy IDEXX Laboratories is operating at the current time. Most of IDEXX Laboratories' value examination focuses on studying past and present price action to predict the probability of IDEXX Laboratories' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move IDEXX Laboratories' price. Additionally, you may evaluate how the addition of IDEXX Laboratories to your portfolios can decrease your overall portfolio volatility.